This strategy is used, herein, to design the new anti-breast cancer agents with PARP-2 inhibitory activity by combining the benzoxazole scaffold10 with a terminal amine via a phenyl reversed amide linker as in hybrids A, B and C, or to combine the benzoxazole moiety with 1,2,3 triazole ring via a phenyl linker as in hybrid D (Fig. 2). This evidence concerns the gene PARP2 and breast carcinoma.